The APP/FE65 Complex in Regulating Neurite Outgrowth

About the Research Project
Program
Award Type
Standard
Award Amount
$100,000
Active Dates
April 01, 2004 - September 30, 2006
Grant ID
A2004255
Summary
Alzheimer’s disease (AD) is believed to be caused by the excess accumulation of amyloid beta (Aß) in the brain. It is well known that Aß is derived through the processing of a larger molecule, the amyloid precursor protein (APP). Determining the function of APP will further an understanding of the pathological events leading to AD and should help to identify therapeutic targets that do not disrupt normal brain functions. Dr. Ikin believes that proteins that bind to APP could potentially modify its function. One such protein is the cytosolic adapter FE65. Dr. Ikin has already shown that APP and FE65 both localize in a region of neuronal growth cones along with mena, which regulates membrane motility and is required for normal neural development. This suggests that a constellation of factors involving APP and FE65 may play a role in growth cone motility. In this project, Dr. Ikin is testing the hypothesis that APP, FE65, and one or more additional proteins form a complex involved in the regulation of growth cone movement and neurite outgrowth. The function of this complex may have direct implications for AD, since the loss of neural connections and neuronal sprouting are prominent features of Alzheimer’s disease pathology.
Grants
Related Grants
Alzheimer's Disease Research
Regulatory Mechanisms Underlying Endosomal Targeting of SORL1
Active Dates
January 01, 2025 - December 31, 2026
Principal Investigator
Olav Andersen, PhD
Current Organization
Max Delbrück Center for Molecular Medicine
Regulatory Mechanisms Underlying Endosomal Targeting of SORL1
Active Dates
January 01, 2025 - December 31, 2026

Principal Investigator
Olav Andersen, PhD
Current Organization
Max Delbrück Center for Molecular Medicine
Alzheimer's Disease Research
The Role of DYRK1A in Altered Microglia Biology in a Cellular Model of Alzheimer’s Disease in Down Syndrome
Active Dates
January 01, 2025 - December 31, 2027
Principal Investigator
Frances Wiseman, PhD
Current Organization
University College London (UK)
The Role of DYRK1A in Altered Microglia Biology in a Cellular Model of Alzheimer’s Disease in Down Syndrome
Active Dates
January 01, 2025 - December 31, 2027

Principal Investigator
Frances Wiseman, PhD
Current Organization
University College London (UK)
Alzheimer's Disease Research
Synergistic Effects of Biological Sex and Sleep Loss in an AD Mouse Model
Active Dates
January 01, 2025 - December 31, 2026
Principal Investigator
Mallar Chakravarty, PhD
Current Organization
Douglas Research Centre
Synergistic Effects of Biological Sex and Sleep Loss in an AD Mouse Model
Active Dates
January 01, 2025 - December 31, 2026
Principal Investigator
Mallar Chakravarty, PhD
Current Organization
Douglas Research Centre